$23.01
0.00%
Nasdaq, Thu, Sep 26 2024
ISIN
US41358P1066
Symbol
HARP
Sector
Industry

Harpoon Therapeutics, Inc. Stock price

$23.01
+0.00 0.00% 1M
+0.00 0.00% 6M
+11.64 102.37% YTD
+18.81 447.86% 1Y
-57.09 71.27% 3Y
-119.09 83.81% 5Y
-111.99 82.96% 10Y
Nasdaq, Closing price Thu, Sep 26 2024
+0.00 0.00%
ISIN
US41358P1066
Symbol
HARP
Sector
Industry

Key metrics

Market capitalization $94.54m
Enterprise Value $77.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.07
P/S ratio (TTM) P/S ratio 2.53
P/B ratio (TTM) P/B ratio 20.82
Revenue growth (TTM) Revenue growth 16.14%
Revenue (TTM) Revenue $37.34m
EBIT (operating result TTM) EBIT $-37.39m
Free Cash Flow (TTM) Free Cash Flow $-69.50m
Cash position $31.61m
EPS (TTM) EPS $-8.71
P/E forward negative
P/S forward 2.25
EV/Sales forward 1.84
Short interest 3.24%
Show more

Is Harpoon Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.

Harpoon Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Harpoon Therapeutics, Inc. forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Harpoon Therapeutics, Inc. forecast:

Hold
100%

Financial data from Harpoon Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
37 37
16% 16%
100%
- Direct Costs 2.82 2.82
1% 1%
8%
35 35
18% 18%
92%
- Selling and Administrative Expenses 12 12
26% 26%
33%
- Research and Development Expense 57 57
30% 30%
152%
-35 -35
49% 49%
-93%
- Depreciation and Amortization 2.82 2.82
1% 1%
8%
EBIT (Operating Income) EBIT -37 -37
47% 47%
-100%
Net Profit -31 -31
57% 57%
-82%

In millions USD.

Don't miss a Thing! We will send you all news about Harpoon Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harpoon Therapeutics, Inc. Stock News

Neutral
Investors Business Daily
6 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
Business Wire
7 months ago
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. “We continue to augment and diversify our oncol...
Neutral
Business Wire
9 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Harpoon Therapeutics, Inc. (NasdaqCM: HARP) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Harpoon will receive $23.00 in cash for each share of Harpoon that they ow...
More Harpoon Therapeutics, Inc. News

Company Profile

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Dalton Smart
Founded 2015
Website www.harpoontx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today